Arrowhead Reports Strong Phase 3 Data for Plozasiran in Rare Triglyceride Disorder

Summary

Arrowhead Pharmaceuticals achieved primary endpoints in its Phase 3 PALISADE trial for plozasiran, significantly reducing triglyceride levels and pancreatitis risk. The results position the drug as a formidable competitor to Ionis’ olezarsen for patients with Familial Chylomicronemia Syndrome.

The finding updates the evidence base in Therapeutics and is worth reading against prior studies on the same endpoint. Clinical-stage and evidence-dependent operators in the lane feel these prints first.

Sources

• OVUM Primary source